Summary slide.png (130.13 kB)

Efficacy, Safety and Immunogenicity of Insulin Aspart Biosimilar SAR341402 Compared with Originator Insulin Aspart in Adults with Diabetes (GEMELLI 1): A Subgroup Analysis by Prior Type of Mealtime Insulin

media

posted on 2021-01-06, 14:32 authored by Viral N. Shah, Edward Franek, Karin Wernicke-Panten, Suzanne Pierre, Bhaswati Mukherjee, Karita Sadeharju

Article full text

The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

History

References

https://link.springer.com/article/10.1007/s13300-020-00992-x

Usage metrics

Read the peer-reviewed publication

Efficacy, Safety and Immunogenicity of Insulin Aspart Biosimilar SAR341402 Compared with Originator Insulin Aspart in Adults with Diabetes (GEMELLI 1): A Subgroup Analysis by Prior Type of Mealtime Insulin

Efficacy, Safety and Immunogenicity of Insulin Aspart Biosimilar SAR341402 Compared with Originator Insulin Aspart in Adults with Diabetes (GEMELLI 1): A Subgroup Analysis by Prior Type of Mealtime Insulin

History

References

Usage metrics

Read the peer-reviewed publication

Categories

Keywords

Licence

Exports